肾淀粉样变性（AL型） 中国就医指南

AL amyloidosis of the kidney is a rare, systemic plasma cell disorder characterized by the deposition of monoclonal immunoglobulin light chains (predominantly lambda) as insoluble, β-pleated sheet amyloid fibrils in renal tissue. These deposits disrupt normal glomerular and tubulointerstitial architecture, leading to progressive proteinuria, nephrotic syndrome, and ultimately end-stage kidney disease if untreated. Pathogenesis begins with clonal expansion of bone marrow plasma cells producing misfolded, aggregation-prone light chains. Unlike multiple myeloma, the plasma cell burden is typically low (<10% in bone marrow), but the secreted light chains are inherently unstable and prone to proteolytic cleavage and fibril formation. Once deposited in the kidney—especially in glomeruli, blood vessels, and interstitium—they trigger chronic inflammation, podocyte injury, endothelial dysfunction, and capillary basement membrane thickening. Epidemiologically, AL amyloidosis affects approximately 8–12 per million people annually worldwide; renal involvement occurs in over 70% of cases at diagnosis, making it the most common organ manifestation. It predominantly affects adults aged 60–75 years, with a slight male predominance (male:female ≈ 1.3:1). Risk factors include advancing age, undiagnosed monoclonal gammopathy of undetermined significance (MGUS), chronic inflammatory conditions, and genetic polymorphisms in genes involved in protein folding and clearance (e.g., SERPINA1, RBP4). Notably, no strong environmental or lifestyle risk factors have been established. Quality of life is profoundly impacted: patients frequently experience debilitating fatigue, edema-related mobility limitations, recurrent infections due to hypoalbuminemia and immunosuppression, anxiety surrounding rapid functional decline, and psychosocial strain from diagnostic delays (median time to diagnosis is 6–12 months). Renal impairment correlates strongly with reduced physical functioning, depression prevalence (up to 40%), and diminished health-related quality of life scores on validated instruments like KDQOL-SF. Early recognition—through serum free light chain assay, 24-hour urine protein electrophoresis, and kidney biopsy with Congo red staining and mass spectrometry confirmation—is critical. Without treatment, median survival after renal involvement is <2 years; with modern risk-adapted therapy, 5-year survival exceeds 60%. However, persistent proteinuria and declining eGFR remain major drivers of long-term morbidity, dialysis dependence, and transplant eligibility challenges.

# 肾淀粉样变性（AL型）治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：早期确诊、心肾功能代偿期、不适合强化化疗者

• •一线药物治疗（含硼替佐米+地塞米松±环磷酰胺）：

- 药物年费用：国产方案 ¥120,000–¥180,000；进口原研方案 ¥260,000–¥350,000

• •支持治疗（利尿、ACEI/ARB控压、营养支持）：年均 ¥8,000–¥15,000

二、核心介入/根治性方案

适用人群：年龄＜70岁、ECOG评分≤2、无严重心功能不全（LVEF≥40%）、适合自体干细胞移植（ASCT）

• •ASCT全流程：

- 干细胞动员+采集+回输+住院监护（28–35天）：¥280,000–¥360,000（含G-CSF、培美曲塞预处理、层流病房）

三、特殊复杂/晚期方案

适用人群：多器官衰竭、耐药复发、透析依赖或合并严重心脏淀粉样变

• •达雷妥尤单抗联合方案（二线）：年治疗费 ¥420,000–¥520,000（含每月静脉输注及感染监测）
• •终末期替代治疗（维持性血液透析+心脏同步化治疗）：年均 ¥120,000–¥180,000

方案快速选择指南

• •预算有限/初诊稳定者 → 优选国产化疗方案（¥12万/年）+规范随访
• •中青年高危可耐受者 → ASCT为唯一可能延长生存的根治路径（首年投入约¥30万）
• •晚期多器官受累者 → 达雷妥尤单抗+对症支持，重在生活质量与症状控制